Does Insurance Cover Peptide Therapy? What Is Covered, What Is Not, and Why

Compounding for an identified individual patient is governed by section 503A of the Federal Food, Drug, and Cosmetic Act. The operative sentence is short: sections 501(a)(2)(B), 502(f)(1) and 505 of the Act "shall not apply to a drug product if the drug product is compounded for an identified individual patient" under the conditions the section sets out.

Those three exempted sections are current good manufacturing practice, adequate directions for use on the label, and new drug approval. The third is the whole story. A compounded preparation is lawful precisely because the approval requirement does not apply to it, and a pharmacy benefit pays for products that went through that requirement. The exemption that makes compounding legal is the same one that makes it unclaimable.

The FDA states it plainly: "Compounded drugs are not FDA-approved. This means that FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed." The same page explains the purpose: "A drug may be compounded for a patient who cannot be treated with an FDA-approved medication."

Read those together and the logic follows. Compounding exists for the patient the approved-product system does not serve, and a formulary is the approved-product system. The two were never designed to meet.

A pharmacy claim is a set of numbers, and the central one is the National Drug Code identifying a specific product from a specific labeler in a specific package size. The NDC Directory covers prescription, over-the-counter and insulin products "manufactured, prepared, propagated, compounded, or processed by registered establishments for commercial distribution," listed under section 510 of the Act.

The phrase that matters is for commercial distribution. A 503A preparation is made pursuant to one prescription for one named patient, so there is no finished-product NDC to price against, and pharmacies that submit compound claims at all usually submit the codes of the individual ingredients instead. It is also why a receipt solves nothing: hand a plan a clear invoice for BPC-157 and it still will not adjudicate, because the field the system needs is empty.

Where a plan does have discretion, medical necessity review asks whether the treatment is appropriate for a coded diagnosis according to accepted standards. For most wellness peptides there is no approved indication, so there is no diagnosis code that pairs with the product in the plan's criteria. A formulary is a list with tiers and negotiated prices, and a compounded peptide is not on it, so the claim is rejected before a reviewer ever reaches the necessity question.

Where a compounding benefit exists, expect some combination of a dollar cap, a requirement that each active ingredient be a covered drug, exclusion of bulk chemical ingredients, and exclusion of preparations that duplicate a commercially available product. A four-peptide preparation such as KLOW fails the ingredient-by-ingredient test immediately, because no component is individually a covered outpatient drug. The blends are the hardest case for a compounding rider, not the easiest.

Section 503A covers patient-specific compounding in a state-licensed pharmacy. Section 503B covers outsourcing facilities, which register with the FDA and are subject to current good manufacturing practice requirements.

Patients sometimes hope the 503B route is more official and therefore coverable. It is more heavily regulated, but a 503B product is still not an FDA-approved drug product and still is not on your formulary. Quality and coverage are separate questions — what a pharmacy shows you about identity and purity is under quality and lab results.

Same molecule, different legal object. The branded product has an approval, a label, an NDC and a negotiated formulary position. A compounded semaglutide preparation has a prescription and a pharmacy. The benefit does not compare active ingredients; it looks up a product identifier. Two preparations containing semaglutide can therefore sit on opposite sides of a coverage line.

Worth stating accurately, because semaglutide and tirzepatide are among the few molecules in this field with large randomized human evidence, and understating it would be as dishonest as overstating BPC-157.

Semaglutide was studied in the STEP program: STEP 1 in the New England Journal of Medicine in 2021 in adults with overweight or obesity, STEP 2 in the Lancet in 2021 where participants also had type 2 diabetes, and STEP 5 in Nature Medicine in 2022 over two years. Mean weight reduction was substantially greater than placebo, in the double digits as a percentage of body weight in the non-diabetic populations. SELECT, in the New England Journal of Medicine in 2023, was a cardiovascular outcomes trial in people with obesity and established cardiovascular disease but without diabetes. Tirzepatide was studied in SURMOUNT-1 in the same journal in 2022 and SURMOUNT-2 in the Lancet in 2023, with SURPASS-2 and SURMOUNT-5 comparing the two molecules directly.

That evidence is why these molecules have approved branded counterparts and why a plan may have criteria for them. It is also why the covered route, where it exists, runs through the branded product rather than a compounded semaglutide or tirzepatide preparation.

• Formulary exclusion. The product is not on the list. There is nothing to authorize.
• Prior authorization. The product is listed but requires documentation first — typically diagnosis, measurements, and a record of prior attempts.
• Benefit exclusion. The plan excludes an entire category, most commonly weight management, regardless of product. This lives in the plan document rather than the formulary, and it most often ends the conversation.

Check the benefit exclusion first. If weight management is excluded outright, the formulary question is moot and direct pay is what remains — a commercial decision rather than an appeal problem, and compounded semaglutide and tirzepatide each have a published cost page for that comparison.

A covered Part D drug is defined by cross-reference to the Medicaid drug rebate statute: a drug available only by prescription and described in section 1927(k)(2)(A)(i)–(iii) of the Social Security Act. That subparagraph describes drugs "approved for safety and effectiveness as a prescription drug under section 505," drugs approved under section 505(j), and a narrow pre-1962 category.

A compounded preparation is exempt from section 505 by operation of 503A. It therefore does not meet the definition of a covered Part D drug, and that is a definitional failure rather than a discretionary one. No plan has authority to waive it.

Part D also incorporates the Medicaid list of excludable categories at section 1927(d)(2). In the statute's own words those include "Agents when used for anorexia, weight loss, or weight gain," "Agents when used to promote fertility," "Agents when used for cosmetic purposes or hair growth," prescription vitamins and minerals other than prenatal vitamins and fluoride, and nonprescription drugs. The implementing regulation says the same: a Part D drug does not include drugs "which may be excluded from coverage or otherwise restricted under Medicaid under sections 1927(d)(2) or (d)(3) of the Act, except for smoking cessation agents."

Read the first category again. An agent when used for weight loss is excludable — a use-based exclusion, which is why the same molecule can be excluded in one prescription and treated differently in another where the documented indication is different and approved.

Two independent failures. The preparation is not a drug approved under section 505, so it is not a covered Part D drug; and if the purpose is weight management, cosmetic effect or hair growth, the use falls inside an excludable category as well. Either alone ends the claim. Part D is not declining to pay for compounded BPC-157 because someone reviewed it and disagreed, but because the statute defines coverage in a way the preparation cannot satisfy.

Part B covers a narrow set of drugs, generally those administered in a physician's office or through durable medical equipment, and is not a route to self-administered compounded peptides. Part A applies to inpatient care. Medicare Advantage plans deliver Part D benefits under the same definition, though some add supplemental benefits; if you are on one, ask whether a supplemental drug benefit exists and what it excludes. CMS publishes the program's coverage materials centrally.

Publication 502 defines the category: "Medical expenses are the costs of diagnosis, cure, mitigation, treatment, or prevention of disease and for the purpose of affecting any part or function of the body."

Notice what is absent: any reference to FDA approval, formulary status or coverage. The tax test and the insurance test are different, which is why an expense your plan will not touch can still be a qualified one.

Publication 502 is explicit: "You can include in medical expenses amounts you pay for prescribed medicines and drugs. A prescribed drug is one that requires a prescription by a doctor for its use by an individual." And on the other side, "Except for insulin, you can't include in medical expenses amounts you pay for a drug that isn't prescribed."

A compounded peptide dispensed against a prescription from a physician licensed in your state meets the description in the first sentence. That is the most useful fact on this page. The same publication treats supplements and vitamins as not includible "unless they are recommended by a medical practitioner as treatment for a specific medical condition," and allows the cost of a weight-reduction program undertaken as treatment for a specific disease diagnosed by a physician, such as obesity.

An HSA is self-directed: you substantiate the expense yourself and keep the records. A health FSA is administered, so the administrator often wants documentation first. A letter of medical necessity is a short note from the prescribing physician naming the condition, the item prescribed and why it is indicated; ask through the same channel you use for dose questions. Keep the prescription label or pharmacy paperwork, the itemized receipt, the letter if one was asked for, and the lab invoice.

Publication 969 is direct: "If you don't use a distribution from your HSA for qualified medical expenses, you must pay tax on the distribution," reported on Form 8889, and "You may have to pay an additional 20% tax." It ties HSA qualified medical expenses to the same section 213(d) definition Publication 502 explains.

Medical expenses can also be itemized, but only the portion above 7.5% of adjusted gross income, and only for expenses "not compensated by insurance or otherwise." Most patients paying for one treatment monthly never reach that threshold, which is why the HSA and FSA route matters more. You cannot do both with the same dollar: Publication 502 states that amounts paid with tax-free distributions from a health savings account or flexible spending arrangement cannot be included as medical expenses. Pick one route per dollar and record which.